ECM
LAB icon

Endurant Capital Management’s Standard BioTools LAB Stock Holding History

Endurant Capital Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-232,291
Closed -$590K – 67
2020
Q1 		$590K Sell
232,291
-802,342
-78% -$2.64M 0.27% 43
2019
Q4 		$3.6M Buy
1,034,633
+638,932
+161% +$2.25M 1.13% 26
2019
Q3 		$1.83M Buy
+395,701
New +$3.12M 0.66% 30
2019
Q1 		– Sell
-236,648
Closed -$2.04M – 80
2018
Q4 		$2.04M Sell
236,648
-325,936
-58% -$2.54M 1.08% 28
2018
Q3 		$4.21M Buy
562,584
+448,474
+393% +$3.19M 1.87% 22
2018
Q2 		$680K Buy
+114,110
New +$650K 0.29% 53
2016
Q3 		– Sell
-256,490
Closed -$2.32M – 99
2016
Q2 		$2.32M Sell
256,490
-286,800
-53% -$2.7M 0.77% 38
2016
Q1 		$4.38M Buy
543,290
+140,000
+35% +$1.01M 1.42% 29
2015
Q4 		$4.36M Sell
403,290
-94,478
-19% -$928K 1.46% 25
2015
Q3 		$4.04M Buy
497,768
+459,568
+1,203% +$7.23M 1.35% 26
2015
Q2 		$924K Buy
+38,200
New +$1.21M 0.27% 65

Other funds holding LAB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PCMI
Paradigm Capital Management Inc Albany, New York $2.61B AUM 78.58% 1-Year Est. Return

Endurant Capital Management's LAB Position: Q2 2020 in Review

Endurant Capital Management sold out of Standard BioTools (LAB) in Q2 2020, closing a stake of 232,291 shares — an estimated $590K sold.

Endurant Capital Management first reported a position in LAB in Q2 2015 and held it in 11 quarters. The position peaked at $4.38M in Q1 2016. 112 funds tracked by Wall St. Rank hold LAB as of Q2 2020.

  • Endurant Capital Management reported no remaining Standard BioTools position as of Q2 2020 after selling out during the quarter.
  • Endurant Capital Management sold 232,291 Standard BioTools shares in Q2 2020, an estimated $590K.
  • Endurant Capital Management first reported a position in Standard BioTools in Q2 2015 and held it in 11 quarters.
  • Endurant Capital Management's Standard BioTools position peaked at $4.38M in Q1 2016.
  • 112 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2020.

Based on Endurant Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.